Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Concerns sort of short term sort of not

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 02, 2020 12:52pm

149 Views

Post# 32018650

RE:RE:RE:Concerns sort of short term sort of not

Well Ogre ... if you get bushwacked ... I get bushwacked.

I've been in since 2017 and luckly ... can't honestly remember being under water with this one.
It helps when your average price is about 15 cents.
Maybe a little higher - was taking advantage of some buying in the low 30's recently.

I say darn the torpidoes on this one.
It's either going to make me happy or break my heart.
I'll take it any way I'm supposed to have it.

: )

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December